← Back
Data updated: Mar 10, 2026
DELCATH SYSTEMS INC
CardiovascularMetabolicOncology
DELCATH SYSTEMS INC is a pharmaceutical company focused on Cardiovascular, Metabolic, Oncology. Key products include HEPZATO.
2023
Since
1
Drugs
-
Trials
5
Approved (2yr)
Recent Activity
HEPZATO 2025-09-04
REMS
HEPZATO 2025-07-30
Labeling
HEPZATO 2024-10-01
REMS
HEPZATO 2024-07-10
Manufacturing (CMC)
HEPZATO 2024-05-22
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Cardiovascular 41%
0 drugs Phase 3: 10 Phase 2: 1
Metabolic 31%
0 drugs Phase 3: 8
Oncology 14%
1 drugs Phase 3: 1 Phase 2: 2
Ophthalmology 10%
0 drugs Phase 3: 2 Phase 2: 1
Dermatology 4%
0 drugs Phase 3: 1
Pipeline Strength Pro
Loading...
Competitors Pro
Bayer big-pharma
Oncology, Cardiovascular, Ophthalmology, Dermatology, Metabolic
Baxter specialty
Cardiovascular, Oncology, Dermatology, Ophthalmology
B BRAUN specialty
Ophthalmology, Dermatology, Metabolic, Cardiovascular
Novartis big-pharma
Oncology, Cardiovascular, Ophthalmology
FOUGERA PHARMS other
Dermatology, Ophthalmology, Oncology, Cardiovascular
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2023-08-14
- Latest
- 2025-09-04
- Applications
- 1